Adaptimmune Therapeutics plc (ADAP) NASDAQ

0.08

-0.0004(-0.50%)

Updated at August 01 04:00PM

Currency In USD

Valuation

Market Cap135.91M
Enterprise Value118.98M
P/E Ratio-0.29
PEG Ratio-0.04
Price/Sales Ratio0.11
Price/Book Ratio-0.55
Enterprise/Revenue0.02
Enterprise/EBITDA-0.05

Fiscal Year

Fiscal YearDecember 31, 2024
Most Recent QuarterMarch 31, 2025

Profitability

Profit Margin-0.39
Operating Margin-0.36

Management Effectiveness

Return On Assets-0.44
Return On Equity-1.86

Income Statement

Revenue178.03M
Revenue/Share0.12
Gross Profit177.96M
EBITDA-52.67M
Net Income-70.81M
Diluted EPS-0.28

Balance Sheet

Total Cash59.56M
Total Cash/Share0.04
Total Debt48.71M
Total Debt/Equity-0.62
Current Ratio2.02
Book Value Per Share-0.02

Price History

52-Week Change-93.17
52-Week High1.33
52-Week Low0.08
Moving Average 50 Days0.25
Moving Average 200 Days0.46

Statistics

Average Volume6.67M
Shares Outstanding257.85M
% Held by Institutions7.53

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split FactorN/A
Last Split DateN/A